Given its differential overexpression in numerous cancers including RMS, and its ability to activate both RAS and PAX3–FOXO1 signaling pathways, AVIL demonstrates promising therapeutic potential as a target for both ERMS and ARMS. This evidence concerns the gene AVIL and cancer.